Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

The phase III CARTITUDE-4 trial reported that receipt of ciltacabtagene autoleucel (cilta-cel) following bridging therapy significantly improved progression-free survival when compared with standard care for patients with lenalidomide-refractory multiple myeloma. 

Median follow-up was 15.9 months (range, 0.1-27.3 months). Median progression-free survival was not reached in the ciltacabtagene autoleucel group vs. 11.8 months (95% CI: 9.7–13.8 months) in the standard-care group (HR = 0.26, 95% CI: 0.18-0.38, P < 0.001). Objective response was observed in 84.6% of patients in the ciltacabtagene autoleucel group vs 67.3% of those in the standard-care group (risk ratio = 2.2, P < 0.001). Among responders, response was ongoing at 12 months in 84.7% vs 63.0%. Overall survival data were immature at time of analysis (HR = 0.78, 95% CI: 0.5–1.2, P = 0.26).